Article summary
In a bold move for European mental health care, Germany has become the first country in the EU to approve psilocybin therapy for patients with treatment-resistant depression outside of clinical trials!This decision, made under a compassionate use framework, marks a significant step forward in the responsible integration of psychedelic-assisted therapies into mainstream medicine. Addressing Unmet […] The post Germany’s Landmark Compassionate Use Program for Psilocybin: A New Wave for Psychedelic Medicine in Europe appeared first on OPEN Foundation.
Continue to the original publication for the complete article.